Autres domaines


Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) - 11/01/21

Doi : 10.1016/j.jaad.2020.09.047 
Mark G. Lebwohl, MD a, , Craig L. Leonardi, MD b, Nehal N. Mehta, MD, MSCE c, Alice B. Gottlieb, MD, PhD d, Alan M. Mendelsohn, MD e, Jeff Parno, MS e, Stephen J. Rozzo, PhD e, M. Alan Menter, MD f, g
a Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York 
b Central Dermatology and Saint Louis University School of Medicine, St Louis, Missouri 
c National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 
d Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York 
e Sun Pharmaceutical Industries, Inc, Princeton, New Jersey 
f Division of Dermatology, Baylor Scott & White, Dallas, Texas 
g Texas A&M College of Medicine, Dallas, Texas 

Reprint requests: Mark G. Lebwohl, MD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th St, New York, NY 10029.Department of DermatologyIcahn School of Medicine at Mount Sinai5 East 98th StNew YorkNY10029



Data for the effect of metabolic syndrome (MetS) on the efficacy and safety of biologic agents for psoriasis treatment are limited.


To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients with psoriasis by baseline MetS status.


Post hoc analyses of up to 3 years of efficacy data and 5 years of safety data from the phase 3, double-blind, randomized controlled reSURFACE 1 and 2 trial (NCT01722331 and NCT01729754) base and extension studies were conducted for patients receiving continuous tildrakizumab 100 or 200 mg.


Of 338 (n = 124/214 in reSURFACE 1/2) and 307 (n = 147/160 in reSURFACE 1/2) patients continuously receiving tildrakizumab 100 and 200 mg, respectively, throughout the studies, 26/44 (21%/21%) and 34/30 (23%/19%) met MetS criteria. Proportions of patients who achieved a 75% improvement in the Psoriasis Area and Severity Index (PASI) in reSURFACE 1/2 were generally comparable among those with versus without MetS at week 52 (tildrakizumab 100 mg, 85%/86% vs 86%/94%; tildrakizumab 200 mg, 76%/87% vs 76%/87%) and through week 148. Results were similar for responders with 90% and 100% improvement in the PASI. Tildrakizumab's safety profile did not vary by MetS status.


Small sample size and post hoc analysis limit interpretation.


Long-term tildrakizumab efficacy and safety were comparable between patients with and without MetS.

Le texte complet de cet article est disponible en PDF.

Key words : clinical research, dermatology, efficacy, interleukin 23, metabolic syndrome, psoriasis, safety, tildrakizumab

Abbreviations used : AE, BMI, CV, CVD, IL, MACE, MedDRA SOC, MetS, NCEP ATP III, PASI, PY, SAE, TEAE


 Funding sources: Funded by Merck Sharp and Dohme, a subsidiary of Merck, Kenilworth, New Jersey. These analyses were funded by Sun Pharmaceutical Industries, Inc.
 Disclosure: Dr Lebwohl is an employee of Mount Sinai; receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer and UCB; and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis; Inc, Avotres Therapeutics, BirchBioMed, Inc, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr Reddy's Laboratories, Serono, Theravance, and Verrica. Dr Leonardi has served as a consultant for and/or has been an investigator for and/or is on the speaker bureaus for AbbVie, Actavis, Amgen, Boehringer Ingelheim, Celgene, Coherus, Corrona, Dermira, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Sandoz, Stiefel, UCB, Vitae, and Wyeth. Dr Mehta is a full-time employee of the US government and has received support in the form of grants to the National Institutes of Health from AbbVie, Celgene, Janssen, and Novartis. Dr Gottlieb has received honoraria as an advisory board member and consultant for Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Sun Pharmaceutical Industries, Inc, UCB, and XBiotech (only stock options, which she has not used) and has received research/educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries Ltd., UCB, and XBiotech. Dr Mendelsohn is an employee of Sun Pharmaceutical Industries, Inc, and has individual shares in Johnson and Johnson and as part of retirement account/mutual funds. Author Parno and Dr Rozzo are employees of Sun Pharmaceutical Industries, Inc. Dr Menter has received grants and/or honoraria as a consultant, investigator, and/or speaker for AbbVie, Abbott Labs, Amgen, Anacor, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Biotech, LEO Pharma, Merck & Co, Novartis, Sienna, and UCB and has been on an advisory board for AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen Biotech, LEO Pharma, and Sienna.
 IRB approval status: Reviewed and approved by local IRB boards at each study site.

© 2020  American Academy of Dermatology, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 2

P. 398-407 - février 2021 Retour au numéro
Article précédent Article précédent
  • Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis
  • Tsung-Yu Tsai, I-Hsin Huang, Yuan-Chen Chao, Hua Li, Tyng-Shiuan Hsieh, Hsiao-Han Wang, Yu-Ting Huang, Chun-Yuan Chen, Ying-Chih Cheng, Po-Hsiu Kuo, Yu-Chen Huang, Yu-Kang Tu
| Article suivant Article suivant
  • Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children
  • Sergey Rekhtman, Rachel Tannenbaum, Andrew Strunk, Morgan Birabaharan, Shari Wright, Amit Garg

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.